Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
年度募集资金使用鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与实际使用情况的专项审核报告" which translates to "Special Audit Report on the Annual Deposit and Actual Use of Raised Funds" for the year 2022. It is issued by an accounting firm (希格玛会计师事务所) and includes detailed audited information about the company's raised funds, their storage, management, and actual usage during the year. The document references regulatory guidelines related to the management and use of raised funds, and contains detailed financial tables and audit opinions. This is a standalone audit report focusing specifically on the raised funds' management and usage, not a full annual report or interim report. It is not an announcement or a brief summary but a detailed audit report. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2022
2023-04-28 Chinese
独立董事事前认可意见
Board/Management Information Classification · 90% confidence The document is titled as an "Independent Directors' Prior Approval Opinion" related to the company's 2023 annual related party transactions and the reappointment of the 2023 audit firm. It contains opinions from independent directors on these matters before the board meeting. The document does not contain actual financial statements or detailed audit results but is an opinion and approval statement regarding audit firm reappointment and related party transactions. It is a governance-related document reflecting board-level oversight and approvals, not a full audit report or annual report. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level approvals and governance matters.
2023-04-28 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司2022年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report verification opinion for the year 2022 by a sponsoring institution (中信建投证券股份有限公司) regarding 天康生物股份有限公司. It discusses internal control evaluation scope, standards for identifying internal control deficiencies, and audit opinions on internal control effectiveness. The document is a verification opinion on the internal control self-evaluation report, not the report itself. It contains detailed internal control assessment and audit opinions but is not a full annual report or audit report standalone. Given the nature of the document as a verification opinion on internal control self-evaluation, it fits best under Audit Report / Information (AR), which includes audit reports and applied accounting principles related to internal controls, excluding full annual reports. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-04-28 Chinese
关于2022年度计提存货跌价准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding the provision for inventory impairment for the fiscal year ending December 31, 2022. It details the amount of inventory write-down, the accounting standards applied, and the impact on the company's profit for 2022. The document includes board and supervisory committee approvals and independent director opinions. The content is focused on a specific accounting adjustment and its rationale rather than a full financial report or earnings release. The document length is 1837 characters, which is relatively short and primarily serves as a regulatory announcement about the inventory impairment provision. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or officer attestation. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2023-04-28 Chinese
关于前期会计差错更正的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Bio Co., Ltd. regarding the correction of prior period accounting errors. It details the nature of the accounting errors, the retrospective adjustments made to financial statements for prior years, and the impact on consolidated and parent company financials. It also includes opinions from the company's board, independent directors, and supervisory board, as well as a special report from an accounting firm on the corrections. The document references compliance with accounting standards and regulatory disclosure rules. The content is focused on correcting previously reported financial information rather than presenting a full annual or interim report. The document length is 4103 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting corrections and does not contain a full financial report or detailed financial statements itself.
2023-04-28 Chinese
未来三年（2023年-2025年）股东回报规划
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2023-2025), including dividend distribution principles, decision-making procedures, and supervisory mechanisms. It references regulatory guidelines from the China Securities Regulatory Commission and company bylaws. The content focuses on dividend policy and shareholder returns rather than financial results, audit opinions, or management changes. It is not a financial report, earnings release, or regulatory filing announcing a report. The document is a formal policy statement issued by the company's board, which aligns with a Notice of Dividend Amount or Dividend Policy Announcement. Given the detailed nature of the dividend policy and planning, the most appropriate classification is Notice of Dividend Amount (DIV). The document length is under 5,000 characters, but it contains substantive policy content rather than just an announcement of a report publication, so it is not RPA or RNS.
2023-04-28 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.